EpiBiologics

# High-Level Overview

EpiBiologics is a biotechnology company developing targeted protein degradation therapies for membrane and extracellular proteins—a therapeutic space largely unexplored by competitors.[1][3] Founded in 2021 and based in San Mateo, California, the company has raised $73 million to date, with its most recent funding of $23 million occurring approximately two years ago.[1]

The company addresses a critical gap in drug development: while existing protein degradation technologies focus on intracellular targets, EpiBiologics targets the approximately 40% of the human proteome consisting of membrane and extracellular proteins that remain clinically unaddressed.[3][4] Its proprietary EpiTAC platform uses bispecific antibodies to selectively degrade disease-causing proteins in a tissue-specific manner, with applications spanning oncology, autoimmune disorders, neurodegeneration, and metabolic diseases.[4] This approach enables the company to attack historically difficult-to-drug targets while minimizing harm to healthy tissue through tissue selectivity.

# Origin Story

EpiBiologics was founded in 2021 (with one source indicating 2022) by Dr. Rami Hannoush and co-founder Dr. Jim Wells, a renowned antibody engineer from the University of California, San Francisco (UCSF).[1][2] The company's foundational intellectual property was exclusively licensed from UCSF, grounding the venture in rigorous academic research.[2]

The company launched publicly in 2022 with $50 million in Series A funding, co-led by Mubadala Capital and Polaris Partners, with participation from Vivo Capital and GV.[2] This substantial initial backing reflected investor confidence in the scientific approach and the market opportunity. Dr. Hannoush, who has served as Chief Scientific Officer since inception, became interim CEO and President, positioning the company to industrialize the EpiTAC platform and validate it across multiple therapeutic applications.[2]

# Core Differentiators

• Novel Target Space: EpiBiologics uniquely focuses on extracellular and membrane protein degradation, expanding beyond the intracellular targets that dominate the protein degradation field.[2][3]

• EpiTAC Platform Architecture: The platform leverages bispecific antibodies—a well-established antibody format with favorable pharmacological properties and scalable manufacturing—rather than small molecules or other modalities.[4] This ensures a clearer path to clinical development.

• EpiAtlas Receptor Library: The company has developed an atlas of over 270 degradation-inducing protein receptors expressed on distinct tissue and cell types, enabling precise pairing of therapeutic targets with tissue-specific degrader receptors.[3][4] This modular approach allows the company to optimize for cell or tissue selectivity across diverse indications.

• Tissue Selectivity: By leveraging tissue-enriched degrader receptors, EpiTACs can achieve disease-selective degradation while sparing healthy tissue, potentially improving the therapeutic index compared to non-selective approaches.[4]

# Role in the Broader Tech Landscape

EpiBiologics operates at the intersection of two powerful biotech trends: the maturation of protein degradation as a therapeutic modality and the expansion of antibody engineering capabilities. While intracellular protein degradation (via PROTACs and other technologies) has gained significant traction, the extracellular proteome remains largely untapped—representing a substantial white space in drug development.

The company's timing is advantageous. As the biotech industry increasingly recognizes the limitations of traditional small-molecule and antibody approaches for certain disease targets, degradation-based therapies offer a fundamentally different mechanism: complete removal of disease-causing proteins rather than mere inhibition. EpiBiologics' focus on extracellular targets positions it to capture value from this shift while addressing diseases currently considered intractable.

The company's academic pedigree and platform approach also reflect a broader ecosystem trend: the translation of cutting-edge university research into specialized biotech ventures with deep scientific moats. By securing exclusive licensing from UCSF and assembling a team of expert antibody engineers, EpiBiologics has built defensible intellectual property that competitors cannot easily replicate.

# Quick Take & Future Outlook

EpiBiologics is well-positioned to establish itself as a leader in extracellular protein degradation, but faces the typical biotech challenges: advancing preclinical programs toward clinical trials, demonstrating safety and efficacy in human subjects, and navigating regulatory pathways for a relatively novel therapeutic modality. The company's pipeline includes programs targeting non-small cell lung cancer (with EGFR and c-MET degrading EpiTACs currently in preclinical stages).[6]

The company's trajectory will depend on several factors: successful advancement of lead candidates into clinical development, validation of tissue selectivity in vivo, and the broader market adoption of degradation therapies. If EpiBiologics can demonstrate clinical proof-of-concept for its platform, it could unlock significant value and establish a new standard for targeting previously undruggable extracellular proteins. The next 18-24 months will be critical as the company moves from platform validation toward clinical translation—a transition that will determine whether the scientific promise translates into therapeutic reality.